Authors: Reasor, Mark J¹; Hastings, Kenneth L²; Ulrich, Roger G³

Source: Expert Opinion on Drug Safety, Volume 5, Number 4, July 2006 , pp. 567-583(17)

Publisher: Informa Healthcare

Abstract:

Numerous drugs containing a cationic amphiphilic structure are capable of inducing phospholipidosis in cells under conditions of in vivo administration or ex vivo incubation. The principal characteristics of this condition include the reversible accumulation of polar phospholipids in association with the development of unicentric or multicentric lamellated bodies within cells. There is an abundance of data providing an understanding of potential mechanisms for the induction of phospholipidosis; however, the process is likely to be complex and may differ from one drug to another. The functional consequences of the presence of this condition on cellular or tissue function are not well understood. The general consensus is that the condition is an adaptive response rather than a toxicological manifestation; however, additional studies to examine this question are needed. Until this issue is resolved, concerns about phospholipidosis will continue to exist at regulatory agencies. Procedures for the screening of potential phospholipogenic candidate compounds are available. In contrast, a clear need exists for the identification of valid biomarkers to assess the development of phospholipidosis in preclinical and clinical studies.

Keywords: drug-induced injury; lysosomal storage disorder; phospholipase; phospholipidosis

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14740338.5.4.567

Affiliations: 1: 1Professor of Toxicology, Robert C Byrd Health Sciences Center of West Virginia University, Department of Physiology and Pharmacology, P.O. Box 9229, Morgantown, WV 26506, USA., Email: mreasor@hsc.wvu.edu 2: 2Associate Director, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20093, USA., Email: kenneth.hastings@fda.hhs.gov 3: 3Senior Scientific Director, Rosetta Inpharmatics LLC, Merck & Co. Inc., 401 Terry Avenue, N. Seattle, WA 98109, USA., Email: roger_ulrich@merck.com

Publication date: 2006-07-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Reasor, Mark J ;  Hastings, Kenneth L ;  Ulrich, Roger G

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers